Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

A New Era in Neuropsychiatry: Dr. Velichka Valcheva on GH Research’s Rapid-Acting Breakthrough, GH001
Shots:   GH001, an inhaled formulation of mebufotenin, is emerging as a highly differentiated therapy for treatment-resistant depression, delivering ultra-rapid and profound symptom improvement – patients come to the clinic depressed and many leave in remission already on the same day. Long term, in a Phase 2b trial, 73% of patients who completed six months were in remission—substantially higher than the…
February 23, 2026
Transforming Lupus Management: Caterina Brindicci Shares AstraZeneca’s Approach to Patient-Focused Care 
Shots:  TULIP-SC full results reinforce efficacy and remission potential with subcutaneous Saphnelo, showing higher disease activity reduction (56.2% vs 34% placebo at Week 52), improved BICLA response, DORIS-defined remission, and reduced oral corticosteroid use, consistent with the IV formulation  Self-administration expands access and adherence, offering flexible at-home or clinic dosing, supporting earlier biologic intervention and steroid…
February 18, 2026
Powering the Next Era of Animal Health: Gary Yang on CPBIO’s Global Strategy 
Shots:  CPBIO’s expanding global footprint is powered by a science-led strategy that connects innovation, partnerships, and emerging market growth with a core goal: turning evidence-based R&D into practical solutions that improve livestock productivity, resilience, and sustainability.  The company delivers species-specific solutions across poultry, swine, ruminants, and aquaculture while following a unified R&D philosophy focused on…
February 16, 2026
Bringing Lupus Care Closer to Patients: Caterina Brindicci on AstraZeneca’s Next Chapter in Immunology
Shots:  AstraZeneca’s patient-focused immunology vision is reinforced by the EU approval of subcutaneous, self-administered Saphnelo (anifrolimab), offering people with SLE a more convenient option that reduces treatment burden, supports earlier biologic use, and advances the goal of remission beyond symptom control  The new formulation is expected to improve access, uptake, and adherence while easing infusion capacity constraints, with regulatory…
February 4, 2026
Pictor Labs at SITC 2025: Megan Rothney on How ClearStain Is Transforming Molecular Sequencing and Precision Oncology
Shots:  ClearStain debuted at SITC 2025 as a workflow-changing innovation, delivering high-quality virtual H&E images from unstained slides to improve tumor identification, reduce sequencing failures, preserve tissue, and accelerate molecular and precision oncology workflows  By enabling direct visualization and annotation of the exact tissue destined for sequencing, ClearStain helps pathologists and molecular labs maximize tumor purity, minimize impurities,…
January 19, 2026
Inside Anavex’s Alzheimer’s Strategy: Dr. Christopher Missling on Blarcamesine, SIGMAR1, and Precision Medicine 
Shots:   Neurodegenerative care is at a pivotal inflection point, shifting from symptomatic relief to strategies that restore cellular resilience. Blarcamesine (ANAVEX 2-73) advances this upstream approach by activating SIGMAR1 to rebalance autophagy, targeting a core driver of neurodegeneration  Phase IIb/III findings demonstrated a statistically significant slowing of cognitive decline, with the most pronounced benefit seen in patients carrying the…
December 22, 2025
Redefining Respiratory Endpoints: Inside Strados Labs’ Vision for Objective, Real-World Lung Monitoring 
Shots:  Clinical trial sponsors are rapidly moving toward objective, continuous respiratory monitoring, adopting technologies like the RESP Biosensor to improve endpoint sensitivity, safety assessments, and real-world patient insight.  Beyond cough frequency, emerging acoustic biomarkers, such as wheezes, crackles, cough intensity, and cough bout patterns, are redefining how respiratory function and therapeutic impact are measured in modern trials.  PharmaShots welcomes Nick Delmonico,…
December 15, 2025
A New Era for Myeloma Patients: Regeneron’s Karen Rodriguez Lorenc on Lynozyfic’s Rising Global Impact 
Shots:  Lynozyfic is emerging as a standout in heavily pre-treated multiple myeloma. In the pivotal LINKER-MM1 trial, it delivered early, deep, and durable responses, offering renewed hope for patients with limited options. Its response-adapted dosing regimen further reduces treatment burden and enhances convenience  Regeneron is accelerating progress with a broad development strategy, advancing Lynozyfic across multiple therapy lines, combination regimens, precursor conditions, and global markets. The program…
December 8, 2025
Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology 
Shots:  Evorpacept emerges as the only CD47-blocking therapy with strong clinical activity and a highly manageable safety profile, thanks to its unique inactive Fc design that enables targeted tumor destruction while sparing healthy cells  Updated ASPEN-06 data highlights CD47 overexpression as a powerful predictive biomarker, showing dramatic improvements in ORR, DOR, PFS, and OS for patients with…
December 3, 2025
Inside Sapient’s Multi-Omics Revolution: A Deep Dive with Founder Mo Jain 
Shots:    Sapient’s new partnership with Alamar Biosciences supercharges its multi-omics engine, bringing the ultra-sensitive NULISA™ platform in-house to capture hard-to-measure cytokines and chemokines, unlocking deeper biological insights beyond the reach of mass spectrometry alone  The collaboration with Rancho Biosciences is redefining large-scale data intelligence, enabling Sapient’s DynamiQ™ platform to seamlessly integrate, structure, and analyze massive multi-omics and real-world…
December 1, 2025
Load more